Inhibrx Biosciences
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11025 N Torrey Pines Rd Ste 140, La Joll...Phone Number
(858) 795-4220Website
www.inhibrx.comRevenue
<$5 MillionStock Symbol
INBXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Inhibrx Biosciences
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.Explore more
Inhibrx Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inhibrx Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Inhibrx Biosciences recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Inhibrx Biosciences has new funding data
Product Launch: Get notified when Inhibrx Biosciences launches new products
Click to see if Inhibrx Biosciences had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Inhibrx Biosciences
Check if Inhibrx Biosciences has recently received funding, and reach out quickly before it becomes old news!
Inhibrx Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Inhibrx Biosciences is spiking on competitors!
Recommended Actions
Find VP level buyers at Inhibrx Biosciences
Find more new buyers
Compare Similar Companies to Inhibrx Biosciences
Compare insights from companies similar to Inhibrx Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Public
$29.8M
1997
LW
Lauren WittberAssociate Director, Accounting, SEC Reporting & Financial Analysis
Company Profile Activity
Activity Insights
Inhibrx Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inhibrx Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inhibrx Biosciences.
Inhibrx Biosciences financials insights
Gather financial insights about Inhibrx Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Debt
$20M
2020
Debt
$1M
Inhibrx Biosciences Tech Stack
A closer look at the technologies used by Inhibrx Biosciences
See more technologies
Most Recent Scoops
Hiring Plans
Inhibrx Biosciences has more open roles in Operations than it has had at any time in the past 12 months. Areas of expertise include: Order Entry.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Finance
Person-Based
Award
Project
Medical Research, Pharmaceuticals
Inhibrx Biosciences News & Media
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second...Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma SAN DIEGO, June 15, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc....Inhibrx Reports First Quarter 2026 Financial Results
SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Recent Corporate Highlights and Upcoming...Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab combination achieved a cORR of 44.0% versus 21.4% with pembrolizumab alone, representing a...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Inhibrx Biosciences
Sign Up For FreeTo access detailed company insights
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or m... Read More
